MedTrace Logo

Evaluation of GM101 Injection in Patients With Parkinson's Disease

NCT07100171 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-08-03

No results posted yet for this study

Summary

The objective of this study is to assess the safety of GM101 in participants with Parkinson's disease (PD)

Conditions

  • Parkinson's Disease

Interventions

OTHER

Biological: GM101

Neurosurgical delivery of GM101 to the putamen

Sponsors & Collaborators

  • Genemagic Biosciences Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-29
Primary Completion
2027-02-17
Completion
2030-02-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07100171 on ClinicalTrials.gov